| Original language | English (US) |
|---|---|
| Pages (from-to) | 312-316 |
| Number of pages | 5 |
| Journal | Journal of Pediatrics |
| Volume | 238 |
| DOIs |
|
| State | Published - Nov 2021 |
All Science Journal Classification (ASJC) codes
- Pediatrics, Perinatology, and Child Health
Keywords
- administrative claims data
- electronic health records
- observational research
- pediatric
- pharmacoepidemiology
- real-world data
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric Populations. / Horton, Daniel B.; Blum, Michael D.; Burcu, Mehmet.
In: Journal of Pediatrics, Vol. 238, 11.2021, p. 312-316.Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric Populations
AU - Horton, Daniel B.
AU - Blum, Michael D.
AU - Burcu, Mehmet
N1 - Funding Information: This article is endorsed by the International Society for Pharmacoepidemiology (ISPE). D.H. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health ( K23AR070286 and R01AR074436 ) and received grant funding from Danisco USA Inc . M.Bu. is a full-time employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and holds stock in Merck & Co., Inc., Kenilworth, NJ, USA. M.Bl. declares no conflicts of interest. This article reflects the views and opinions of the authors and should not be construed to represent the views and opinions of the US government, the US Food and Drug Administration, the National Institutes of Health, or any other public or private entity, who had no role in the writing of the report or the decision to submit the paper for publication. Funding Information: This article is endorsed by the International Society for Pharmacoepidemiology (ISPE). D.H. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (K23AR070286 and R01AR074436) and received grant funding from Danisco USA Inc. M.Bu. is a full-time employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and holds stock in Merck & Co., Inc., Kenilworth, NJ, USA. M.Bl. declares no conflicts of interest. This article reflects the views and opinions of the authors and should not be construed to represent the views and opinions of the US government, the US Food and Drug Administration, the National Institutes of Health, or any other public or private entity, who had no role in the writing of the report or the decision to submit the paper for publication.
PY - 2021/11
Y1 - 2021/11
KW - administrative claims data
KW - electronic health records
KW - observational research
KW - pediatric
KW - pharmacoepidemiology
KW - real-world data
UR - http://www.scopus.com/inward/record.url?scp=85110515152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110515152&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2021.06.062
DO - 10.1016/j.jpeds.2021.06.062
M3 - Comment/debate
C2 - 34217767
AN - SCOPUS:85110515152
VL - 238
SP - 312
EP - 316
JO - Journal of Pediatrics
JF - Journal of Pediatrics
SN - 0022-3476
ER -